ERBB2 and gastric cancer: CAR-T cells offer a viable therapeutic avenue for advanced GC by exhibiting promising efficacy in targeting biomarkers such as CLDN 18.2, HER2, mucin 1, natural killer receptor group 2, and mesothelin [128,129,130].